IRTC Stock Crash: iRhythm Plunges 30% After Q3 Earnings Miss & Zio MCT Delay
1 extracted signal · 0 resolved · 1 still active
Global News DailyIndependent analyst profile- Source published
- 08 Nov 2026, 10:37 UTC
- Recorded by Tahlil Plus
- 08 Nov 2026, 14:19 UTC

AI-generated source summary
iRhythm Technologies experienced a severe 30.44% single-session sell-off, plunging to $90.22 following an unexpected FDA audit request regarding packaging design controls and customer notifications. Despite this headline overhang and a negative operating loss of $56.2 million driven by aggressive R&D and legal remediation, the company maintains robust fundamentals with $558.4 million in trailing 12-month revenue, an impressive 67.8% gross margin, and a comfortable 3.5 to 4-year cash runway. The core technological moat rests on the Zio platform's 14-day continuous AI-integrated monitoring and its proprietary Zeus AI system trained on 1 billion hours of ECG data. Three probabilistic future scenarios are modelled: a base case (50% probability) targeting $110-$125 over 6-9 months assuming FDA inquiries resolve; a bull case (30% probability) targeting $145-$165 driven by rapid international expansion in Japan; and a bear case (20% probability) targeting $65-$75 if regulatory friction escalates. Overall, the stock is classified as a speculative contrarian buy, heavily dependent on the formal issuance of the FDA inspection close-out letter (EIR) to unlock shareholder value.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Global News Daily
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
